Assessing Omega-3 Fatty Acid Supplementation During Pregnancy and Lactation to Optimize Maternal Mental Health and Childhood Cognitive Development

Chelsea M Klemens; Kataneh Salari; Ellen L Mozurkewich


Clin Lipidology. 2012;7(1):93-109. 

In This Article

Future Perspective

More work is needed to determine whether EPA or DHA or a combination of both may be beneficial for mothers at risk for perinatal depression. Likewise, the role for omega-3 fatty acid supplementation for neonates at greatest risk for suboptimum development, such as those born preterm or after perinatal hypoxia–ischemia requires further study. DHA, or its derivative NPD1, may ultimately be shown to have a neuroprotective role in perinatal hypoxia–ischemia, but this potential use is speculative at the current time, as it has been only tested in animal models. It is unclear whether the more beneficial therapeutic approaches will be established for maternal and infant dietary supplementation with omega-3 long-chain PUFAs among mother–infant dyads at the highest risk for suboptimal cognitive development, or whether stable synthetic analogs of resolvins and protectins, the bioactive metabolites of omega-3 fatty acids, will find therapeutic uses.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: